Espitia De La Hoz Franklin José
Ginecología y Obstetricia, Universidad Militar Nueva Granada, Bogotá, Colombia; Sexología Clínica, Universidad de Alcalá de Henares, Madrid, España; Uroginecología, FUCS, Hospital de San José, Unicamp, Brasil; Hathor, Clínica Sexológica, Armenia, Colombia.
Rev Int Androl. 2023 Jan-Mar;21(1):100328. doi: 10.1016/j.androl.2021.09.002. Epub 2022 Nov 5.
To determine the efficacy and safety of testosterone in the treatment of hypoactive sexual desire in women.
A systematic review of the literature was carried out in different electronic databases (CINAHL, DynaMed, EMBASE, Lilacs, Medline, Scopus, among others), between January 1990 and May 2021; through standardized search terms. The outcomes evaluated included the efficacy and safety of testosterone in increasing sexual desire, the total number of satisfactory sexual activity, the number of orgasms and the level of distress in patients with hypoactive sexual desire and the proportion of adverse reactions.
72 articles were included. The use of testosterone, in postmenopausal women, with hypoactive sexual desire, reports a positive effect on sexual function, with significant increases in satisfactory sexual activity, as well as improvement in all domains of sexual function (desire, arousal and orgasmic response) and a decrease in personal anguish, with an increase in the Female Sexual Function Index score. In women of childbearing age, testosterone is formulated for "off-label" use, in such a way that compounds and doses designed for treatments in men or magisterial formulas are used (which are not approved by consensus groups or endorsed by research), but has not shown any effect on sexual function. The most frequent adverse reactions are usually hirsutism and acne, although in general testosterone, at physiological doses, has a favorable safety profile.
Testosterone is an effective and safe therapy in the treatment of hypoactive sexual desire disorder in women after menopause. Currently there are no studies available to support the use of testosterone therapy in women of reproductive age, therefore, its use is not approved.
确定睾酮治疗女性性欲减退的疗效和安全性。
于1990年1月至2021年5月期间，通过标准化检索词，在不同电子数据库（包括CINAHL、DynaMed、EMBASE、Lilacs、Medline、Scopus等）中对文献进行系统综述。评估的结果包括睾酮在增加性欲方面的疗效和安全性、满意性活动的总数、性高潮次数、性欲减退患者的痛苦程度以及不良反应的比例。
纳入72篇文章。对于绝经后性欲减退的女性，使用睾酮对性功能有积极影响，满意性活动显著增加，性功能的所有方面（性欲、性唤起和性高潮反应）均有改善，个人痛苦减轻，女性性功能指数评分增加。对于育龄期女性，睾酮用于“非标签”用途，即使用为男性治疗设计的化合物和剂量或法定配方（未得到共识小组批准或研究认可），但对性功能未显示出任何影响。最常见的不良反应通常是多毛症和痤疮，不过一般而言，生理剂量的睾酮具有良好的安全性。
睾酮是治疗绝经后女性性欲减退障碍的有效且安全的疗法。目前尚无研究支持在育龄期女性中使用睾酮疗法，因此，其使用未获批准。
